Source comparison
Tesamorelin vs CJC-1295
CJC-1295 is a GHRH analogue incorporating drug affinity complex (DAC) technology that enables albumin binding, extending its half-life to approximately 6–8 days and permitting once- or twice-weekly dosing rather than the once-daily schedule required by tesamor
This comparison does not assign a generated winner or score.
- CJC-1295 is a GHRH analogue incorporating drug affinity complex (DAC) technology that enables albumin binding, extending its half-life to approximately 6–8 days and permitting once- or twice-weekly dosing rather than the once-daily schedule required by tesamorelin. This pharmacokinetic difference arises from a fundamental structural design choice: CJC-1295’s albumin-binding technology dramatically extends its circulating duration. However, CJC-1295 remains a research compound with no FDA-approved indication and a substantially more limited published clinical dataset than tesamorelin. No Phase 3 randomised controlled trials with meaningful clinical endpoints (body composition, metabolic markers, cognitive function) have been published for CJC-1295. From an evidence quality standpoint, tesamorelin holds a substantially stronger position in the scientific literature.